Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction
Journal of Medicinal Chemistry · 10.04.2025 · 68 (7) · 7291-7312
DOI: 10.1021/acs.jmedchem.4c02206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.03.2025. Verfasst von Tian Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen, Drug Design, Isoindoles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support, Chinese Institutes for Medical Research, R&D Program of Beijing Municipal Education Commission.
Abstract (Originalsprache)
A novel series of 5-phenylisoindoline derivatives were designed, synthesized, and evaluated for their activity to inhibit the interaction of PD-1/PD-L1 through the homogeneous time-resolved fluorescence assay. Meanwhile, structure-activity relationships were discussed according to both experiments and calculations. Several compounds exhibited potent activity with an IC50 value less than 10 nM, especially D6 (4.8 nM). D6 could promote IFN-γ secretion and reduce the proportion of PD-L1 late apoptosis at 100 nM in the coculture model of peripheral blood mononuclear cells and hPD-L1-FC. Beyond this, the in vitro model showed D6 could lead to the weakening of migration caused by the PD-1/PD-L1 axis. Furthermore, D6 also displayed dose-dependent and low-toxic efficacy in the MC38 mouse tumor model with the tumor growth inhibition of 52.8% (20 mg/kg, ip) and 64.4% (160 mg/kg, i.g.). Mechanistic investigations suggested that D6 could activate the immune microenvironment in the tumor. Thus, D6 is a promising small molecule lead for blocking PD-1/PD-L1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
- Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing Key Laboratory of Drug Innovation for Neuro-Oncology, Beijing Laboratory of Biomedical Materials, Beijing Laboratory of Oral Health, Laboratory…
ORCID-Profile: Tian Lu
Förderung
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
- Chinese Institutes for Medical Research
- R&D Program of Beijing Municipal Education Commission
- Beijing Key Laboratory Program
- Beijing Great Wall Scholar Program
Zitieren
APA
Lu, T., Zhang, J., Chen, Q., Ni, M., Zhang, J., Wu, Y., Jia, R., & Wang, Y. (2025). Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction. Journal of Medicinal Chemistry, 68(7), 7291-7312. https://doi.org/10.1021/acs.jmedchem.4c02206
Vancouver
Lu T, Zhang J, Chen Q, Ni M, Zhang J, Wu Y, et al. Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction. Journal of Medicinal Chemistry. 2025;68(7):7291-7312. doi:10.1021/acs.jmedchem.4c02206
BibTeX
@article{Lu2025,
author = {Lu, Tian and Zhang, Jiyi and Chen, Qiyu and Ni, Mengyue and Zhang, Jingwen and Wu, Yufei and Jia, Ruining and Wang, Yuji},
title = {Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {7},
pages = {7291--7312},
doi = {10.1021/acs.jmedchem.4c02206}
}
EUVIMED